#USA #New York #Class Action #Investor Rights #NowRx

Attention NowRx Investors: Class Action Lawsuit Filed

Bronstein, Gewirtz & Grossman, LLC, a well-known firm dedicated to investor rights, has announced a class action lawsuit against NowRx, Inc. This lawsuit aims to help individuals and entities who invested in NowRx securities between February 1, 2022, and November 5, 2022.

What Happened with NowRx?

The central claim of the lawsuit is that NowRx and its executives failed to disclose crucial information about the company's financial health. Key allegations include:

• - The firm was on the verge of bankruptcy or insolvency.
• - NowRx had engaged an investment bank to explore a sale or to raise substantial capital for continuity.
• - Contrary to its Series C stock offering price of $10.50 per share in 2022, an evaluation in late 2021 was set at just $3.55 per share by a credible investment bank.

Given this discrepancy, shareholders who purchased stock during the Series C round faced significant risks of losing their investments.

Next Steps for Investors

Affected NowRx investors should act swiftly. They can join the class action lawsuit by visiting bgandg.com/nowrx or by reaching out to esteemed attorney Peretz Bronstein at 917-590-0911. The court-appointed lead plaintiff deadline is January 23, 2026, although participating in recovery does not necessitate serving as a lead plaintiff.

No Upfront Costs for Participants

Investors should note that Bronstein, Gewirtz & Grossman LLC continues to represent clients on a contingency fee basis. The firm will only collect fees from any recovery attained, ensuring no upfront financial burden on investors involved in the class action.

Why Choose Bronstein, Gewirtz & Grossman?

This law firm has a solid reputation within the legal landscape, specializing in securities fraud and class action lawsuits. With a track record of recovering hundreds of millions in damages for clients nationwide, their commitment to investor rights is unwavering. Peretz Bronstein, the firm's founding partner, emphasized, 'Our mission is to restore investor capital and hold corporations accountable, maintaining the crucial integrity of the financial markets.'

For ongoing updates regarding the lawsuit and corporate affairs, investors are encouraged to follow the firm through various social media platforms, including LinkedIn, X, Facebook, and Instagram.

In summary, NowRx investors are encouraged not to hesitate and to take action promptly given the implications of this lawsuit. The lawsuit aims to recover losses tied to the alleged misrepresentations and omissions concerning NowRx’s true financial state, which could negatively impact investors significantly. Therefore, affected individuals are advised to review their options before the deadline approaches.